読み込み中
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
前日終値
$4.81
−$0.04 · -0.82%
日中の時刻はETです。市場データは遅延する場合があります。
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
日中レンジ
現在 $4.81
52週レンジ
現在 $4.81
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
中立
バリュエーション
57
適正価値
センチメント
69
強気
リスク
70
高リスク
モメンタム
22
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
日中レンジ
現在 $4.81
52週レンジ
現在 $4.81
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 1.34億 USD | 1.4億 USD | 8907.7万 USD | 4900.5万 USD | 2259.3万 USD |
| 売上原価 | 3146.9万 USD | 4098.4万 USD | 3531.2万 USD | 2767.7万 USD | 1807.6万 USD |
| 粗利益 | 1.03億 USD | 9894.3万 USD | 5376.5万 USD | 2132.8万 USD | 451.7万 USD |
| 研究開発 | 3854.9万 USD | 3436.7万 USD | 2905.1万 USD | 2598.1万 USD | 2449.9万 USD |
| 販売・一般管理 | 1.13億 USD | 1.01億 USD | 7479.9万 USD | 5866.5万 USD | 3280.5万 USD |
| 営業費用 | 1.51億 USD | 1.36億 USD | 1.04億 USD | 8464.6万 USD | 5730.4万 USD |
| 受取利息 | 250.8万 USD | 947.4万 USD | 657.4万 USD | 151.7万 USD | 5.4万 USD |
| 支払利息 | 4万 USD | 2.1万 USD | 330.8万 USD | 494.6万 USD | 368.2万 USD |
| 減価償却費と償却費 | 326.6万 USD | 362.4万 USD | 424.3万 USD | 402.2万 USD | 398.8万 USD |
| 営業利益 | −4819万 USD | −3685.8万 USD | −5008.5万 USD | −6331.8万 USD | −5278.7万 USD |
| 純利益 | −3894.3万 USD | −2745.5万 USD | −4860.8万 USD | −6675.6万 USD | −4868.8万 USD |
会社概要が更新されました 2026年10月11日.
発表済み実績と利用可能なコンセンサス予想。
発表済み実績と利用可能なコンセンサス予想。
この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI899.5万0.00%2.3兆 USD0.03%$381.94+0.63%
iShares Russell 2000 ETFIWM509.69万0.01%787.4億 USD0.19%$278.94+0.49%
Vanguard Extended Market ETFVXF300.01万0.00%954億 USD0.05%$235+0.80%
Vanguard Russell 2000 ETFVTWO168.24万0.01%180億 USD0.06%$112.66+0.50%
Schwab U.S. Small-Cap ETFSCHA96.71万0.00%218.24億 USD0.03%$32.79+0.40%
Vanguard Health Care ETFVHT87.57万0.00%220億 USD0.09%$319.01+1.64%
iShares Micro-Cap ETFIWC60.61万0.05%13.17億 USD0.60%$183+0.11%
Invesco RAFI US 1500 Small-Mid ETFPRFZ31.01万0.01%26.7億 USD0.36%$53.16+0.64%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWOSchwab U.S. Small-Cap ETFSCHAVanguard Health Care ETFVHTiShares Micro-Cap ETFIWCInvesco RAFI US 1500 Small-Mid ETFPRFZAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
